Myasthenia.org Website Review

the myasthenia gravis foundation of america (mgfa) is the only national volunteer health agency in the united states dedicated solely to the fight against myasthenia gravis. mgfa serves patients, their families and caregivers.   myasthenia gravis (pronounced my-as-theen-ee-a grav-us) comes from the greek and latin words meaning grave muscular weakness. the most common form of mg is a chronic autoimmune neuromuscular disorder that is characterized by fluctuating weakness of the voluntary muscle their drug, zilucoplan (formerly called ra101495) in treating myasthenia gravis, for people with achr+ antibodies. the company also announced plans to engage with regulatory agencies, including the us fda, regarding the design of a phase 3 trial in early 2019 for people. new treatment for lambert-eaton myasthenic syndrome (lems) receives fda approval. catalyst pharmaceuticals has announced that the u.s. fda has approved firdapse® (amifampridine) 10mg for the treatment of lambert-eaton myasthenic syndrome (lems) in ad*lts 18 years or older. catalyst will work to ensure access to firdapse® for those diagnosed with lems with as little out-of-pocket burden as possible. we have also established catalyst pathways™, our patient service program, to provide a single source for one-on-one personalized support through a dedicated team of specialists. patients and families can learn more by visiting. mgfa produced emergency management training video for nurses & first responders. the mgfa has produced an educational training video for first responders and emergency health providers. the video covers myasthenic crisis and how to manage mg in an emergency situation. help spread this important information by calling the administration office of your local er about this opportunity for continuing education for nurses or by offering to set up a meeting to show the video to first. ucb accelerates anti-fcrn rozanolixizumab in myasthenia gravis into confirmatory development phase.